World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
95
Citations
30455
World Ranking
906
National Ranking
81

Medicine

D-Index
96
Citations
30660
World Ranking
9756
National Ranking
949

Research.com Recognitions

  • 1974 - Member of the National Academy of Sciences

Overview

John D. Isaacs is a researcher affiliated with Newcastle University in the United Kingdom, with a focus on medicine and more specifically rheumatology. Their work covers various subfields including immunology, hematology, radiology, nuclear medicine and imaging, and genetics. Their research spans a variety of topics related to immune-mediated and inflammatory diseases.

Isaacs has contributed extensively to the study of rheumatoid arthritis and other autoimmune disorders. Some of the main topics of their work include:

  • Rheumatoid Arthritis Research and Therapies
  • Systemic Lupus Erythematosus Research
  • Monoclonal and Polyclonal Antibodies Research
  • Autoimmune and Inflammatory Disorders Research
  • Biosimilars and Bioanalytical Methods
  • Chronic Lymphocytic Leukemia Research
  • T-cell and B-cell Immunology

Isaacs' recent publications demonstrate research activity in clinical trials, treatment consensus, and biomarker analysis. Notable papers include:

  • "Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial" (2021, The Lancet)
  • "Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement" (2020, Annals of the Rheumatic Diseases)
  • "EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2" (2020, Annals of the Rheumatic Diseases)
  • "Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial" (2022, Nature Medicine)
  • "Single-cell sequencing reveals clonal expansions of pro-inflammatory synovial CD8 T cells expressing tissue-homing receptors in psoriatic arthritis" (2020, Nature Communications)

Their frequent co-authors include:

  • Arthur G. Pratt
  • Anne Barton
  • Ann W. Morgan
  • Kimme L Hyrich
  • Darren Plant

Isaacs has published in multiple journals with repeated contributions to:

  • Annals of the Rheumatic Diseases
  • Lara D. Veeken
  • The Lancet Rheumatology
  • RMD Open
  • Arthritis & Rheumatology

Isaacs' research portfolio includes over 300 publications in medicine, with a significant focus on rheumatology as represented by 129 publications in that subfield. Other notable subfields include immunology and hematology.

Isaacs was recognized with the award of Member of the National Academy of Sciences in 1974.

Best Publications

  • The value of sonography in the detection of bone erosions in patients with rheumatoid arthritis: a comparison with conventional radiography.

    Richard J. Wakefield;Wayne W. Gibbon;Philip G. Conaghan;Philip O'Connor

  • Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls

    Nick Craddock;Matthew E. Hurles;Niall Cardin;Richard D. Pearson

  • Human CD4(+)CD25(+) cells: a naturally occurring population of regulatory T cells.

    Wan Fai Ng;Phillip J. Duggan;Frederique Ponchel;Giuseppe Matarese

  • Cytokines in rheumatoid arthritis - shaping the immunological landscape.

    Iain B. McInnes;Christopher D. Buckley;John D. Isaacs

  • Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis

    M.H. Buch;J.S. Smolen;N. Betteridge;F.C. Breedveld

  • Real-time PCR based on SYBR-Green I fluorescence: An alternative to the TaqMan assay for a relative quantification of gene rearrangements, gene amplifications and micro gene deletions

    Frederique Ponchel;Carmel Toomes;Kieran Bransfield;Fong T Leong

  • Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial

    Iain B. McInnes;Joachim Sieper;Juergen Braun;Paul Emery

  • Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial.

    Joel Kremer;Zhan-Guo Li;Stephen Hall;Roy Fleischmann

  • Frailty and the role of inflammation, immunosenescence and cellular ageing in the very old: Cross-sectional findings from the Newcastle 85+ Study

    Joanna Collerton;Carmen Martin-Ruiz;Karen Davies;Catharien M. Hilkens

  • Elucidation of the relationship between synovitis and bone damage: A randomized magnetic resonance imaging study of individual joints in patients with early rheumatoid arthritis

    Philip G. Conaghan;Philip O'Connor;Dennis McGonagle;Paul Astin

  • Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naïve with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE))

    Paul Emery;A. Deodhar;W. F. Rigby;J. D. Isaacs

  • Adult Human Fibroblasts Are Potent Immunoregulatory Cells and Functionally Equivalent to Mesenchymal Stem Cells

    Muzlifah A. Haniffa;Xiao-Nong Wang;Udo Holtick;Michelle Rae

  • Integrated safety in tocilizumab clinical trials.

    Michael H Schiff;Joel M Kremer;Angelika Jahreis;Emma Vernon

  • Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers

    Philip M. Brown;Arthur G. Pratt;John D. Isaacs

  • Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn’s disease and ulcerative colitis?

    Kenneth F Baker;John D Isaacs;John D Isaacs

  • Humanised monoclonal antibody therapy for rheumatoid arthritis.

    J D Isaacs;R A Watts;B L Hazleman;G Hale

  • Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells.

    Mark G. Wing;Thibault Moreau;Judith Greenwood;Richard M. Smith

  • Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial

    Unknown

  • Autologous tolerogenic dendritic cells for rheumatoid and inflammatory arthritis

    G M Bell;A E Anderson;J Diboll;R Reece

  • Early rheumatoid arthritis is associated with a deficit in the CD4+CD25high regulatory T cell population in peripheral blood

    C. A. Lawson;A. K. Brown;V. Bejarano;S. H. Douglas

  • Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis

    C Potter;K L Hyrich;A Tracey;M Lunt

  • Biologic therapies in rheumatology: lessons learned, future directions

    Vibeke Strand;Robert Kimberly;John D. Isaacs

Frequent Co-Authors

Ann W. Morgan
Ann W. Morgan University of Leeds
Anne Barton
Anne Barton University of Manchester
Paul Emery
Paul Emery University of Leeds
Anthony G. Wilson
Anthony G. Wilson University College Dublin
Kimme L. Hyrich
Kimme L. Hyrich University of Manchester
Catharien M. U. Hilkens
Catharien M. U. Hilkens Newcastle University
Herman Waldmann
Herman Waldmann University of Oxford
Iain B. McInnes
Iain B. McInnes University of Glasgow
Christopher D. Buckley
Christopher D. Buckley University of Oxford
Andrew Filer
Andrew Filer University of Birmingham

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in Immunology, exploring related healthcare fields can open up diverse career opportunities. Those looking for practical entry points into healthcare may consider LPN programs. Identifying the best easiest lpn programs to get into can help beginners start their careers efficiently while gaining essential patient care skills.

Advancing further, nurse practitioner degrees offer specialized clinical roles. If flexibility and program accessibility are priorities, knowing which nurse practitioner program is easiest can be valuable for choosing the right path without compromising quality education.

Mental health is a growing area within healthcare where Immunology and psychiatry intersect, particularly in research on neuroimmunology. For those interested in clinical practice, exploring the best online psychiatric mental health nurse practitioner programs provides options with strong clinical placement support.

Cost is often a critical factor in education decisions. Students can find affordable training by reviewing cheap psych np programs that offer quality coursework without excessive financial burdens.

Best Scientists Citing John D. Isaacs

Trending Scientists